Trial Profile

Descartes-08 for Patients With Systemic Lupus Erythematosus

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 20 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Descartes 08 (Primary)
Indications Systemic lupus erythematosus
Focus Adverse reactions
Acronyms SLE-001
Sponsors Cartesian Therapeutics

Most Recent Events

13 Jan 2025 According to a Cartesian Therapeutics media release, the company announced that a data readout for this trial is expected in the second half of 2025.
02 Jul 2024 According to a Cartesian Therapeutics media release, the first patient has been dosed in its Phase 2 open-label clinical trial; Trial to assess outpatient administration without lymphodepleting chemotherapy in patients with SLE
08 May 2024 According to a Cartesian Therapeutics media release, dosing of first patient in Phase 2 trial of Descartes-08 in patients with SLE expected in second quarter of 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com